Predictive Factors for Major Bleeding Risk in Patients Admitted in a Palliative Care Unit (RHESO)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01056978 |
Recruitment Status
:
Completed
First Posted
: January 27, 2010
Last Update Posted
: August 7, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Hemorrhage |
Study Type : | Observational |
Actual Enrollment : | 1230 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Predictive Factors for Major Bleeding Risk in Patients Admitted in a Palliativecare Unit - Etude RHESO - Etude Monocentrique |
Study Start Date : | April 2010 |
Actual Primary Completion Date : | December 2012 |
Actual Study Completion Date : | December 2012 |
Group/Cohort |
---|
patients
Patients admitted in a palliative care unit
|
- The primary outcome is the symptomatic occurrence of major and clinical relevant bleeding during the three months study period. [ Time Frame: 3 month ]
- Predictive factors for major bleeding [ Time Frame: 3 month ]
- Incidence of venous thomboembolic symptomatic disease [ Time Frame: 3 month ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- 18 years
- admitted in a palliative care unit for a cancer, a pulmonary, a cardiac or a neurologic advanced disease
Exclusion Criteria:
- life prognosis less than 48 hours
- patients treated with curative doses of antithrombotic therapy
- patients with follow up of 3 months is not possible

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01056978
France | |
Centre Gérontologique Saint-Thomas | |
Aix en Provence, France, 13100 | |
Hôpital Jean Minjoz - CHU de Besançon | |
Besançon, France, 25000 | |
CH de Chambéry | |
Chambery, France, 73011 | |
Hôpital Nord - CHU Clermont-Ferrand | |
Cébazat, France, 63118 | |
CH de Gap | |
GAP, France, 05000 | |
La Maison de Gardanne | |
Gardanne, France, 13120 | |
CHU Grenoble | |
Grenoble, France, 38043 | |
CH Saint-Philibert | |
Lomme, France, 59462 | |
CH Luynes - CHU Tours | |
Luynes, France, 37230 | |
Hôpital Saint-Eloi - CHU de Montpellier | |
Montpellier, France, 34295 | |
CHU Nantes | |
Nantes, France, 44000 | |
CHU Nice | |
Nice, France, 06200 | |
Maison Médicale Jeanne Garnier | |
Paris, France, 75015 | |
Hôpital Sainte Perrine - APHP | |
Paris, France, 75016 | |
GH Diaconnesses Croix Saint-Marie | |
Paris, France, 75571 | |
CHU Lyon Sud | |
Pierre Bénite, France, 69495 | |
CH Puteaux | |
Puteaux, France, 92800 | |
CHU de Saint-Etienne | |
Saint-Etienne, France, 42100 | |
Hôpital Joseph Ducuing - CH Saint-Gaudens | |
Toulouse, France, 31076 | |
Hôpital Paul Brousse APHP | |
Villejuif, France, 94800 |
Study Director: | Bernard TARDY, PHD | CIC-EC (CIE3) |
Responsible Party: | Centre Hospitalier Universitaire de Saint Etienne |
ClinicalTrials.gov Identifier: | NCT01056978 History of Changes |
Other Study ID Numbers: |
0908039 2009-A01234-53 ( Other Identifier: AFSSAPS ) |
First Posted: | January 27, 2010 Key Record Dates |
Last Update Posted: | August 7, 2013 |
Last Verified: | August 2013 |
Keywords provided by Centre Hospitalier Universitaire de Saint Etienne:
palliative care unit bleeding thromboembolic hemorrhagic risk antithrombotic prophylaxis |
Additional relevant MeSH terms:
Hemorrhage Pathologic Processes |